Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.980
+0.010 (1.07%)
Nov 20, 2024, 4:00 PM EST - Market closed
Jaguar Health Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 10.48 | 9.76 | 11.96 | 4.34 | 9.39 | 5.78 | Upgrade
|
| Revenue Growth (YoY) | -2.25% | -18.36% | 175.80% | -53.81% | 62.51% | 30.77% | Upgrade
|
| Cost of Revenue | 2.09 | 2.04 | 2.02 | 2.33 | 3.16 | 3.82 | Upgrade
|
| Gross Profit | 8.4 | 7.72 | 9.94 | 2 | 6.22 | 1.96 | Upgrade
|
| Selling, General & Admin | 22.78 | 23.05 | 26.71 | 26 | 20 | 20.44 | Upgrade
|
| Research & Development | 15.47 | 18.6 | 17.65 | 15.08 | 6.41 | 5.82 | Upgrade
|
| Operating Expenses | 38.26 | 41.64 | 44.35 | 41.08 | 26.41 | 26.26 | Upgrade
|
| Operating Income | -29.86 | -33.92 | -34.42 | -39.07 | -20.19 | -24.3 | Upgrade
|
| Interest Expense | -0.59 | -6.38 | -12.72 | -8.42 | -2.79 | -5.73 | Upgrade
|
| Other Non Operating Income (Expenses) | -8.75 | -4.93 | 0.93 | -2.72 | -2.51 | 1.09 | Upgrade
|
| EBT Excluding Unusual Items | -39.2 | -45.23 | -46.21 | -50.21 | -25.48 | -28.94 | Upgrade
|
| Asset Writedown | -0.37 | -0.37 | - | - | -0.12 | -4 | Upgrade
|
| Other Unusual Items | 1.25 | 3.7 | -2.19 | -2.39 | -8.21 | -5.59 | Upgrade
|
| Pretax Income | -38.33 | -41.9 | -48.4 | -52.6 | -33.81 | -38.53 | Upgrade
|
| Income Tax Expense | - | - | - | - | - | 0.01 | Upgrade
|
| Earnings From Continuing Operations | -38.33 | -41.9 | -48.4 | -52.6 | -33.81 | -38.54 | Upgrade
|
| Minority Interest in Earnings | 0.58 | 0.6 | 0.94 | 0.01 | - | - | Upgrade
|
| Net Income | -37.74 | -41.3 | -47.45 | -52.6 | -33.81 | -38.54 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | 4.84 | 6.19 | Upgrade
|
| Net Income to Common | -37.74 | -41.3 | -47.45 | -52.6 | -38.65 | -44.73 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 0 | 0 | - | - | - | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 0 | 0 | - | - | - | Upgrade
|
| Shares Change (YoY) | 2313.78% | 1658.88% | - | - | - | - | Upgrade
|
| EPS (Basic) | -8.22 | -107.42 | -2170.91 | - | - | - | Upgrade
|
| EPS (Diluted) | -8.23 | -107.42 | -2170.91 | - | - | - | Upgrade
|
| Free Cash Flow | -29.03 | -33.24 | -33.18 | -34.98 | -15.29 | -20.46 | Upgrade
|
| Free Cash Flow Per Share | -6.32 | -86.46 | -1517.96 | - | - | - | Upgrade
|
| Gross Margin | 80.10% | 79.13% | 83.11% | 46.18% | 66.31% | 33.92% | Upgrade
|
| Operating Margin | -284.92% | -347.51% | -287.85% | -901.36% | -215.09% | -420.76% | Upgrade
|
| Profit Margin | -360.13% | -423.11% | -396.91% | -1213.26% | -411.81% | -774.48% | Upgrade
|
| Free Cash Flow Margin | -276.96% | -340.56% | -277.53% | -806.83% | -162.87% | -354.23% | Upgrade
|
| EBITDA | -27.94 | -31.91 | -32.43 | -37.36 | -18.46 | -22.56 | Upgrade
|
| EBITDA Margin | -266.56% | - | -271.28% | - | -196.69% | - | Upgrade
|
| D&A For EBITDA | 1.92 | 2.01 | 1.98 | 1.72 | 1.73 | 1.74 | Upgrade
|
| EBIT | -29.86 | -33.92 | -34.42 | -39.07 | -20.19 | -24.3 | Upgrade
|
| EBIT Margin | -284.92% | - | -287.85% | - | -215.09% | - | Upgrade
|
| Revenue as Reported | 0.72 | - | - | 4.34 | - | 5.78 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.